Investor Presentation | August 2024

Safe Harbor

This presentation contains express "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow Health, Inc. (the "Company" or "Harrow"). Some of these risks and uncertainties include, but are not limited to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Harrow expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. The Company's compounded formulations are not FDA approved. All trademarks, service marks and trade names included in this presentation are the property of their respective owners. This presentation refers to non-GAAP financial measures, specifically adjusted EBITDA, Core Results, such as core gross margin, core net income and core diluted net income per share, and equity values of equity positions in non-controlled investments. A reconciliation and/or further description of any non-GAAP measures with the most directly comparable GAAP measures are included in the Company's Letters to Stockholders, available on its website. All content included in this presentation is intended for investors and the investment community and is not intended as marketing material or for use by healthcare professionals and their patients.

Investment Highlights

Recent Product Launches and Re-Launches are Fueling Profitable and Sustainable Growth

Aggregate annual revenue potential of $500M+ by 2027:

1. **IHEEZO** – launched May of 2023; growth continuing in 2024 and beyond
2. **VEVYE** – launched January 2024; large market category-leading potential
3. **TRIESENCE** – re-launch as early as 2024; strong customer affinity product
4. **Anterior Segment** – high margin and stable portfolio re-launched in Q4 '23
5. **ImprimisRx** – stable cash producer; expecting >10% revenue growth in '24

Throughout 2024, aggregate core gross margins will continue to float up into the 80% range, with meaningful growth in Adjusted EBITDA

MELT-300 Phase 3 results in Q4 of 2024; potential launch in 1H 2026

Harrow's Ophthalmic Pharmaceutical Brands

Ocular Surface

- IHEEZO® (chloroprocaine HCl ophthalmic gel) 3%
- Flarex® (fluorometholone acetate ophthalmic suspension) 0.1%
- Maxidex® (dexamethasone ophthalmic suspension) 0.1%
- Maxitrol® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension)
- Natacyn® (natamycin ophthalmic suspension) 5%
- ZERVIATE® cetirizine ophthalmic solution, 0.24% — FORMULATED WITH HYDRELLA®
- vevye™ (cyclosporine ophthalmic solution) 0.1%
- TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% — FORMULATED WITH XanGen®
- Verkazia® cyclosporine ophthalmic emulsion 0.1%
- Vigamox® (moxifloxacin HCl ophthalmic solution) 0.5% as base
- FRESHKOTE® Preservative Free LUBRICANT EYE DROPS
- Moxeza® (moxifloxacin HCl ophthalmic solution) 0.5% as base

Anterior Segment

- ILEVRO® (nepafenac ophthalmic suspension) 0.3%
- IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) 1% as base Sterile
- IOPIDINE 0.5% (apraclonidine hydrochloride ophthalmic solution) 0.5% as base Sterile
- Nevanac® (nepafenac ophthalmic suspension) 0.1%

Posterior Segment

- Triesence® (triamcinolone acetonide injectable suspension) 40 mg/mL



imprimis Rx® A HARROW COMPANY

Financial Metrics *(in thousands)*



Consolidated Revenues



Adjusted EBITDA[(1)]

(1) Adjusted EBITDA is defined as net loss, excluding the effects of stock-based compensation and expenses, interest, taxes, depreciation, amortization, investment (income) loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net loss. Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net loss as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.

Covered Lives* for Select Products



*Of the estimated 314 million Americans with a pharmacy benefit.

IHEEZO

- Ocular anesthetic gel with broad indication for all ocular anesthetic use cases
- Product-specific J-code (J-2403)
- Separately reimbursable for unilateral and bilateral same-day procedures
- Orange Book-listed patent; claims expiring in 2039

IHEEZO Quarterly Customer Unit Demand*

(beginning with May 2023 launch)

*Customer Unit Demand reflects the number of units purchased by surgery centers, clinic/group practices, and physicians from Harrow's distributors. This metric began in May 2023, and It is not representative of net sales or revenues on a GAAP basis.

VEVYE

The first and only water-free cyclosporine (0.1%) to treat the signs and symptoms of dry eye disease

In a pre-clinical ex-vivo corneal penetration study, VEVYE's vehicle delivered ~22x more cyclosporine into the cornea than Restasis

Orange book-listed patents with expiry in 2039

166 million covered lives; 80% of Medicaid beneficiaries

VEVYE Quarterly Prescriptions

(beginning with January 2024 launch)
(PhilRx Only; Excludes Retail Channel)

TRIESENCE

Preservative-free triamcinolone acetonide suspension

Key on-label indications[1]

- Visualization During Vitrectomy (420,000 procedures per year)
- Posterior Uveitis (100,000 diagnoses per year)

Five-year history of being on FDA's Drug Shortage List

Harrow intends to relaunch TRIESENCE as early as 2024

Product-specific J-Code (J-3300)

Orange book-listed patent, expiring in 2029

[1] Data on visualization of vitrectomy obtained from Definitive Health 2023; data on posterior uveitis obtained from MedScape.

Anterior Segment Products

Portfolio includes:

- Steroids, NSAIDs, and Anti-inflammatories
- An OTC preservative-free lubricant
- An Antihistamine, and Antibiotics
- The only FDA-approved Antifungal
- Medication to treat vernal keratoconjunctivitis, a rare disease
- Anti-glaucoma medications

"Workhorse" products in U.S. optometry and ophthalmology offices

Flarex® (fluorometholone acetate ophthalmic suspension) 0.1%

FRESHKOTE® Preservative Free LUBRICANT EYE DROPS

ILEVRO (nepafenac ophthalmic suspension) 0.3%

Maxidex® (dexamethasone ophthalmic suspension) 0.1%

Verkazia® cyclosporine ophthalmic emulsion 0.1%

Maxitrol® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension)

Natacyn® (natamycin ophthalmic suspension) 5%

Nevanac® (nepafenac ophthalmic suspension) 0.1%

TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05%

Vigamox® (moxifloxacin HCl ophthalmic solution) 0.5% as base

IOPIDINE® (apraclonidine hydrochloride ophthalmic solution) 1% as base

ZERVIATE® cetirizine ophthalmic solution, 0.24%

ImprimisRx

- Leading U.S. ophthalmic-focused compounding business
- More than 15,000 U.S. customers
- 50-state dispensing capabilities
- Broad therapeutic product portfolio
- >10% revenue growth expected in 2024
- 2Q24 record revenues of $21.6 million

imprimis Rx®

Revenues*

(Dollars in thousands)



**Excludes revenue From DEXYCU® in all years; 2023 revenues reflect sale of Company's non-ophthalmic business.*

NOTE: ImprimisRx revenue data is for compounded products, which are not FDA approved; they are cash pay and a custom Rx is needed.

Equity Ownership – Melt Pharmaceuticals



For more details on Melt Pharmaceuticals and its MELT-300 product, go to meltpharma.com.

- Melt Pharmaceuticals, a former subsidiary of Harrow
- MELT-300 is a non-IV and non-opioid sublingual sedation drug candidate for short-duration medical procedures
- MELT-300 is patented in the U.S. and key global markets
- Potential impact in >100 million short-duration procedures
- Robust Phase 2 data for MELT-300 reported in December 2022
- Topline Phase 3 clinical data for MELT-300 expected in 4Q 2024
- MELT-300, when FDA-approved, would replace the MKO Melt, a compounded product sold by Harrow's ImprimisRx subsidiary
- Harrow also owns a 5% royalty interest and a right-of-first-refusal on the commercialization of MELT-300

Commitment to Supporting Mission Trips

Mission Trip to Guatemala
April 2023

Benevolent Missions Intl (Belize)
June 2023

Vision Outreach Intl (Amazon)
October 2023

See Intl (Honduras)
April 2024

During 2023, Harrow's donations served nearly 12,000 patients in over 26 countries.

To date, in 2024, Harrow has committed donations to help over 8,000 patients in over 20 countries.

> "We are proud to have never turned down an opportunity to provide Harrow products to ophthalmologists and optometrists helping to give the gift of sight to our fellow brothers and sisters in the U.S. and across the globe."

Mark L. Baum,
Chief Executive Officer and Founder

HARROW®

102 Woodmont Blvd., Suite 610
Nashville, Tennessee 37205
www.Harrow.com

Jamie Webb
Director of Communications
and Investor Relations
jwebb@harrowinc.com
Direct: 615-733-4737